In vitro and in vivo cytotoxic activity of human lactoferricin derived antitumor peptide R-DIM-P-LF11-334 on human malignant melanoma
Metrics: PDF 1938 views | HTML 2495 views | ?
Sabrina Riedl1,6, Beate Rinner2, Helmut Schaider3,4, Bernadette Liegl-Atzwanger5, Katharina Meditz2, Julia Preishuber-Pflügl1,6, Sarah Grissenberger1,6, Karl Lohner1,6 and Dagmar Zweytick1,6
1Institute of Molecular Biosciences, University of Graz, Graz, Austria
2BioTechMed, Graz, Austria
3Biomedical Research, Medical University of Graz, Graz, Austria
4Cancer Biology Unit, Department of Dermatology, Medical University of Graz, Graz, Austria
5Dermatology Research Centre, The University of Queensland, School of Medicine, Southern Clinical Division, Woolloongabba, Brisbane, Queensland, Australia
6Institute of Pathology, Medical University of Graz, Graz, Austria
Dagmar Zweytick, email: [email protected]
Beate Rinner, email: [email protected]
Keywords: human melanoma, antitumor peptide, cancer treatment, phosphatidylserine, mouse xenograft
Received: February 08, 2017 Accepted: April 11, 2017 Published: May 11, 2017
Di-peptides derived from the human host defense peptide lactoferricin were previously described to specifically interact with the negatively charged lipid phosphatidylserine exposed by cancer cells. In this study one further derivative, namely R-DIM-P-LF11-334 is shown to exhibit even increased cancer toxicity in vitro and in vivo while non-neoplastic cells are not harmed.
In liposomal model systems composed of phosphatidylserine mimicking cancerous and phosphatidylcholine mimicking non-cancerous membranes the specific interaction with the cancer marker PS was confirmed by specific induction of membrane perturbation and permeabilization in presence of the peptide. In vitro studies with cell lines of human malignant melanoma, such as A375, or primary cells of human melanoma metastases to the brain, as MUG Mel1, and non-neoplastic human dermal fibroblasts NHDF revealed high cytotoxic effect of R-DIM-P-LF11-334 on melanoma cells of A375 and MUG Mel1, whereas only minor effect on the dermal fibroblasts NHDF was observed, yielding an about 20-fold killing-specificity for A375 and MUG-Mel1. The LC50 values for melanoma A375 and MUG Mel1 were about 10 μM. Analysis of secondary structure of the peptide revealed an increase in the proportion of β-sheets exclusively in presence of the cancer mimic. Stability studies further indicated a potential adequate stability in blood or under stringent conditions. Importantly the cytotoxic effect on cancer cells was also proven in vivo in mouse xenografts of human melanoma, where peptide treatment induced strong tumor regression and in average a tumor area reduction of 85% compared to tumors of control mice without peptide treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.